ProstatilenПростатилен
What is it?
A prostate-tissue-derived polypeptide preparation with historical urological clinical reports. It is distinct from the synthetic short peptide Prostamax.
Research context
A prostate-tissue-derived polypeptide preparation with historical urological clinical reports. It is distinct from the synthetic short peptide Prostamax.
- Working classification
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Clinical reports linked; see study-specific limitations
- Study methods
- —Original reports separated from narrative reviews and patents
- Independent replication
- —Independent replication not established by this collection
- Source access
- —Linked abstracts, analytical papers, reviews and patents; individual scope shown below
- Safety evidence
- —Incomplete assessment; findings do not establish safety for personal use
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Where this preparation fits.
Prostate: the molecular link
Prostatilen → Prostamax (adjacent short-peptide program)
Tissue-level research association only in this collection; direct molecular derivation of Prostamax from the clinical Prostatilen formulation has not been established.
Clinical boundary
The 307-patient and 52-patient reports concern Prostatilen extract, with control and methods limitations.
Do not assign the Prostatilen cohorts to Prostamax or treat uncontrolled improvement as proof of efficacy.
Related preparations
The contextual sources below can concern a related extract, review or molecular link. They are not all direct studies of this profile’s compound.
Linked sources
Explore the research map and unresolved leads ↗
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
- Population / setting
- Originating group’s clinical and gerontology literature
- What was checked
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Limitations & review scope
- Review by investigators in the originating program; not independent replication.
- Clinical findings must be traced to the exact preparation and original study.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.
The use of prostatilen in treating patients with chronic prostatitis
Tkachuk VN, Gorbachev AG, Khavinson VKh · Urol Nefrol (Mosk) (6):40-43. PMID 1823682
An early tissue-derived prostate-preparation report describes symptom, laboratory and urodynamic changes after treatment, with follow-up at 4–6 months.
- Population / setting
- 307 men with chronic prostatitis
- What was checked
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Limitations & review scope
- The abstract does not establish a randomized concurrent control.
- Reported tolerability cannot establish long-term safety; findings do not apply to Prostamax.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.
The use of prostatilen in treating patients with prostatic diseases
Vozianov AF, Gorpinchenko II, Boĭko NI, Drannik GN, Khavinson VKh · Urol Nefrol (Mosk) (6):43-46. PMID 1823683
Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.
- Population / setting
- 37 patients with chronic prostatitis and 15 with prostatic adenoma
- What was checked
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Limitations & review scope
- Small mixed clinical groups; control methods and adverse-event ascertainment unclear from the abstract.
- The tissue extract is not the synthetic peptide Prostamax.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.